Free Trial
NASDAQ:INVA

Innoviva Q2 2025 Earnings Report

Innoviva logo
$19.92 -0.24 (-1.19%)
As of 01:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Innoviva EPS Results

Actual EPS
$0.77
Consensus EPS
$0.57
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A

Innoviva Revenue Results

Actual Revenue
$100.28 million
Expected Revenue
$87.10 million
Beat/Miss
Beat by +$13.18 million
YoY Revenue Growth
N/A

Innoviva Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Innoviva's Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Tuesday, November 4, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Innoviva Earnings Headlines

Theravance Completes Enrollment in Phase 3 CYPRESS Study
Innoviva (NASDAQ:INVA) Lowered to Buy Rating by Wall Street Zen
This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
Innoviva (NASDAQ:INVA) Stock Rating Upgraded by Wall Street Zen
What is HC Wainwright's Forecast for Innoviva Q3 Earnings?
See More Innoviva Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email.

About Innoviva

Innoviva (NASDAQ:INVA) engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

View Innoviva Profile

More Earnings Resources from MarketBeat